<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Semin Arthritis Rheum</journal-id><journal-id journal-id-type="iso-abbrev">Semin Arthritis Rheum</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Seminars in arthritis and rheumatism</journal-title></journal-title-group><issn pub-type="ppub">0049-0172</issn><issn pub-type="epub">1532-866X</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11088978</article-id><article-id pub-id-type="pmcid-ver">PMC11088978.319</article-id><article-id pub-id-type="pmcaid">11088978</article-id><article-id pub-id-type="pmcaiid">11088978</article-id><article-id pub-id-type="manuscript-id">NIHMS1973553</article-id><article-id pub-id-type="pmid">38457949</article-id><article-id pub-id-type="doi">10.1016/j.semarthrit.2024.152421</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1973553</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1973553</article-id><article-version article-version-type="pmc-version">319</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9750-5448</contrib-id><name name-style="western"><surname>McDermott</surname><given-names initials="GC">Gregory C</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>DiIorio</surname><given-names initials="M">Michael</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawano</surname><given-names initials="Y">Yumeko</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jeffway</surname><given-names initials="M">Mary</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>MacVicar</surname><given-names initials="M">Megan</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dahal</surname><given-names initials="K">Kumar</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Moon</surname><given-names initials="SJ">Su-Jin</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Seyok</surname><given-names initials="T">Thany</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Coblyn</surname><given-names initials="J">Jonathan</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Massarotti</surname><given-names initials="E">Elena</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weinblatt</surname><given-names initials="ME">Michael E.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Weisenfeld</surname><given-names initials="D">Dana</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4797-3200</contrib-id><name name-style="western"><surname>Liao</surname><given-names initials="KP">Katherine P</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Rheumatology, Inflammation, and Immunity, Brigham and Women&#8217;s Hospital, Boston, MA, USA</aff><aff id="A2"><label>2</label>Harvard Medical School, Boston, MA, USA</aff><aff id="A3"><label>3</label>Division of Rheumatology, Department of Internal Medicine, Yeouido St. Mary&#8217;s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea</aff><author-notes><corresp id="CR1"><label>*</label><bold>Corresponding Author:</bold> Gregory C. McDermott, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women&#8217;s Hospital, 60 Fenwood Road, Boston, MA 02115, <email>gmcdermott@partners.org</email></corresp></author-notes><pub-date pub-type="ppub"><month>6</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>01</day><month>3</month><year>2024</year></pub-date><volume>66</volume><issue-id pub-id-type="pmc-issue-id">462239</issue-id><fpage>152421</fpage><lpage>152421</lpage><pub-history><event event-type="nihms-submitted"><date><day>14</day><month>03</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>01</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-01 00:25:39.977"><day>01</day><month>06</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1973553.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P1">Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD switching and investigated characteristics associated with treatment refractory RA.</p></sec><sec id="S2"><title>Methods:</title><p id="P2">In a multi-hospital RA electronic health record (EHR) cohort, we identified RA patients prescribed &#8805;1 b/tsDMARD between 2001-2017. Consistent with the EULAR &#8220;difficult to treat&#8221; (D2T) RA definition, we further identified patients who discontinued &#8805;2 b/tsDMARDs with different mechanisms of action. We performed manual chart review to determine reasons for medication discontinuation. We defined &#8220;treatment refractory&#8221; RA as not achieving low disease activity (&lt;3 tender or swollen joints on &lt;7.5mg of daily prednisone equivalent) despite treatment with two different b/tsDMARD mechanisms of action. We compared demographic, lifestyle, and clinical factors between treatment refractory RA and b/tsDMARD initiators not meeting D2T criteria.</p></sec><sec id="S3"><title>Results:</title><p id="P3">We identified 6040 RA patients prescribed &#8805;1 b/tsDMARD including 404 meeting D2T criteria. The most common reasons for medication discontinuation were inadequate response (43.3%), loss of efficacy (25.8%), and non-allergic adverse events (13.7%). Of patients with D2T RA, 15% had treatment refractory RA. Treatment refractory RA patients were younger at b/tsDMARD initiation (mean 47.2 vs. 55.2 years, p&lt;0.001), more commonly female (91.8% vs. 76.1%, p=0.006), and ever smokers (68.9% vs. 49.9%, p=0.005). No RA clinical factors differentiated treatment refractory RA patients from b/tsDMARD initiators.</p></sec><sec id="S4"><title>Conclusions:</title><p id="P4">In a large EHR-based RA cohort, the most common reasons for b/tsDMARD switching were inadequate response, loss of efficacy, and nonallergic adverse events (e.g. infections, leukopenia, psoriasis). Clinical RA factors were insufficient for differentiating b/tsDMARD responders from nonresponders.</p></sec></abstract><kwd-group><kwd>rheumatoid arthritis</kwd><kwd>disease modifying antirheumatic drugs</kwd><kwd>biological therapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>